HOT NEWS
Abbott announces CE Mark for world's longest coronary drug eluting stent » Abbott today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary ...
Bayer HealthCare joins forces with Stroke Alliance for Europe » Ahead of the "Move for Health Day" (10 May) and the "European Stroke Day" (14 May), the Stroke Allia...
Sanofi strengthens its French-German partnership » Sanofi (EURONEXT: SAN and NYSE: SNY) announced its involvement in two major Franco-German projects ...
Merck Serono to finance the launch of the EspeRare Foundation » Merck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Fo...
Bayer HealthCare to broaden strategic alliance with German Cancer Research Cente... » Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful s...
AstraZeneca and Karolinska Institutet to create Integrated Translational Researc... » AstraZeneca and the Swedish medical university Karolinska Institutet announced today their intention...
Innovative cervical screening app launches in UK and Ireland » The new Roche cobas® HPV Test app for iPad, which provides essential information about cervical can...
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressi... » Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) has appr...
Novartis receives EU approval for Ilaris® in patients suffering acute gouty art... » Novartis announced that the European Commission (EC) has approved llaris (canakinumab, ACZ885) in th...
Genzyme Receives Company Award from European Organisation for Rare Diseases (EUR... » Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), ahas received a Company Award from EURORDIS...
Abbott
AbbottAbbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. For more information, please visit http://www.abbott.com

Abbott RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Abbott announces CE Mark for world's longest coronary drug eluting stent 183
2 Abbott's HUMIRA® (Adalimumab) approved for severe active pediatric Crohn's disease 4376
3 Abbott announces CE Mark and European launch of next-generation XIENCE Xpedition™ 3002
4 Abbott again named one of the Best Workplaces in Europe 4192
5 Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe 3683
6 Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC) 4353
7 First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy 5699
8 EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets 9249
9 Abbott Announces European Launch of TREK(TM) Catheter System 10537
10 Abbott Honored as a Great Place to Work Across Europe 10212
11 Abbott Completes Acquisition of Solvay Pharmaceuticals 12443
12 Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline 11379
13 Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes 10274
14 Abbott to Acquire Solvay Pharmaceuticals Business 10271
15 Abbott to Acquire Visiogen, Expanding Vision Care Portfolio 9145
16 Abbott Reports Strong Second Quarter Results 8428
17 Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent 7987
18 Abbott's XIENCE V(R) Demonstrates Impressive Results in SPIRIT V Study 4468
19 New data to be presented on Abbott's market-leading XIENCE V(R) stent 2715
20 Abbott Reports 16 Percent Earnings Growth in First Quarter 2139
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2